| Literature DB >> 30337494 |
Katharina Fuchs1, Yamel Cardona Gloria1, Olaf-Oliver Wolz1, Franziska Herster1, Lokesh Sharma2, Carly A Dillen3, Christoph Täumer4, Sabine Dickhöfer1, Zsofia Bittner1, Truong-Minh Dang1, Anurag Singh5, Daniel Haischer6, Maria A Schlöffel6, Kirsten J Koymans7, Tharmila Sanmuganantham1, Milena Krach1, Thierry Roger8, Didier Le Roy8, Nadine A Schilling9, Felix Frauhammer10,11, Lloyd S Miller3, Thorsten Nürnberger6, Salomé LeibundGut-Landmann12, Andrea A Gust6, Boris Macek4, Martin Frank13, Cécile Gouttefangeas1, Charles S Dela Cruz2, Dominik Hartl5,14, Alexander Nr Weber15.
Abstract
Chitin is the second most abundant polysaccharide in nature and linked to fungal infection and asthma. However, bona fide immune receptors directly binding chitin and signaling immune activation and inflammation have not been clearly identified because polymeric crude chitin with unknown purity and molecular composition has been used. By using defined chitin (N-acetyl-glucosamine) oligomers, we here identify six-subunit-long chitin chains as the smallest immunologically active motif and the innate immune receptor Toll-like receptor (TLR2) as a primary fungal chitin sensor on human and murine immune cells. Chitin oligomers directly bind TLR2 with nanomolar affinity, and this fungal TLR2 ligand shows overlapping and distinct signaling outcomes compared to known mycobacterial TLR2 ligands. Unexpectedly, chitin oligomers composed of five or less subunits are inactive, hinting to a size-dependent system of immuno-modulation that appears conserved in plants and humans. Since blocking of the chitin-TLR2 interaction effectively prevents chitin-mediated inflammation in vitro and in vivo, our study highlights the chitin-TLR2 interaction as a potential target for developing novel therapies in chitin-related pathologies and fungal disease.Entities:
Keywords: N‐acetyl‐glucosamine; anti‐fungal innate immunity; chitin; inflammation; toll‐like receptor
Mesh:
Substances:
Year: 2018 PMID: 30337494 PMCID: PMC6280652 DOI: 10.15252/embr.201846065
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807